Research Article
Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers
Table 2
Parameter estimates for simulations in Figure
4.
| Drug/Carriera | Mechanisms | Variables | Model parametersb | | | (10−21J) |
| | Pore size | 12.9 nm | 0.192M | — | — | Telmisartan MSNP [30] | 7.8 nm | 0.1M | — | — | | 3.6 nm | 0.0652M | — | — |
| | Amine additive | no additive | 3.913D | 0.013D | 5.11 |
Retinoid Am80PEG-PBLA [11] | TPA | 7.314D | 0.067D | 6.84 | DMDA | 1.272D | 0.059D | 6.61 | | DMOA | 0.541D | 0.001D | −1.18 |
| | Medium ion strength | 0.15 M NaCl | 0.381H | 0.023H | 3.36 |
DSPLNP [10] | 15 mM NaCl | 0.248H | 0.001H | 4.90 | 0.5 mM NaCl | 0.258H | 0.012H | 0.64 | | DDI water | 0.237H | 0.005H | −5.1 |
| | Copolymer composition | PLA/PGA 50 : 50 | 0.197D | 0.019D | −1.69 | Estradiol PLGA [12] | PLA/PGA 65 : 35 | 0.163D | 0.004D | −2.40 | | PLA/PGA 85 : 15 | 0.179D | 0.007D | −3.94 |
|
Savoxepine PLA [13] | Particle size | 303 nm | 1.437D | 0.064D | −0.61 | 671 nm | 1.792D | 0.028D | −5.52 |
| | Composition and molecular weight | PLGA 8,000 | 0.333D | 0.336D | −1.06 |
Steroids PLA/PLGA [9] | PLGA 13,000 | 0.375D | 0.04D | −1.56 | PLA 9,000 | 0.319D | 0.004D | −3.2 | | PLA 14,000 | 0.099D | 0.128D | −6.73 | | Control (BDP) | PLA 14,000 | 5.576D | 0.344D | −0.67 |
|
|
aMSNP: mesoporous silica nanoparticle; PEG-PBLA: polyethylene glycol-poly(benzyl L-aspartate); DMDA: N,N-dimethyldodecylamine; DMOA: N,N-dimethyloctadecylamine; TPA: triphenylamine; DS: dextran sulfate sodium; PLNPs: polymer-lipid hybrid nanoparticles; PLLA: poly(L-lactide).
b and have different units in difference cases: M: minute−1, H: hour−1, and D: day−1.
|